Sex, sleep, steroids, and lifestyle: Unraveling the coronavirus disease 2019 conundrum

Sehgal, Vasudha; Kalra, Amit; Singh, Surender; Ulmer, Brian

doi:10.2478/jtim-2020-0021

Cited by 3 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 14 , 15 ] However, some will become seriously ill and require medical attention. [ 16 , 17 , 18 , 19 ] Older individuals and those with underlying medical conditions, such as cardiovascular disease, chronic respiratory disease, diabetes, and cancer, are more likely to have serious illnesses. [ 20 , 21 , 22 , 23 ] Anyone can get sick with COVID-19 and become seriously ill or die at any age.…”

Section: Discussionmentioning

confidence: 99%

Characteristics of the severe acute respiratory syndrome coronavirus 2 omicron BA.2 subvariant in Jilin, China from March to May 2022

Liu

Wang

Yang

et al. 2022

Journal of Translational Internal Medicine

View full text Add to dashboard Cite

Background and Objectives In the midst of the pandemic, new coronavirus mutants continue to emerge; the most relevant variant worldwide is omicron. Here, patients who recovered from the disease living in Jilin Province were analyzed to identify factors affecting the severity of omicron infection and to provide insights into its spread and early indication. Methods In this study, 311 cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were divided into two groups. Data on the patients’ demographic characteristics and laboratory tests, including platelet count (PLT), neutrophil count (NE), C-reactive protein (CRP), serum creatinine (SCR), and neutrophil-to-lymphocyte ratio (NLR), were collected. The biomarkers for moderate and severe coronavirus disease 2019 (COVID-19) and factors affecting the incubation period and time to subsequent negative nucleic acid amplification test (NAAT) were also investigated. Results Age, gender, vaccination, hypertension, stroke, chronic obstructive pulmonary disease (COPD)/chronic bronchitis/asthma, and some laboratory tests were statistically different between the two groups. In the receiver operating characteristic (ROC) analysis, PLT and CRP had higher area under the ROC curve values. In the multivariate analysis, age, hypertension, COPD/chronic bronchitis/asthma, and CRP were correlated with moderate and severe COVID-19. Moreover, age was correlated with longer incubation. In the Kaplan-Meier curve analysis, gender (male), CRP, and NLR were associated with longer time to subsequent negative NAAT. Conclusions Older patients with hypertension and lung diseases were likely to have moderate or severe COVID-19, and younger patients might have a shorter incubation. A male patient with high CRP and NLR levels might take more time to turn back negative in the NAAT.

show abstract

Section: Discussionmentioning

confidence: 99%

Characteristics of the severe acute respiratory syndrome coronavirus 2 omicron BA.2 subvariant in Jilin, China from March to May 2022

Liu

Wang

Yang

et al. 2022

Journal of Translational Internal Medicine

View full text Add to dashboard Cite

show abstract

Is Trikatu an ayurvedic formulation effective for the management of flu-like illness? A narrative review

Javed¹,

Dixit

2021

Journal of Complementary and Integrative Medicine

View full text Add to dashboard Cite

Objectives The aim of this review is to summarise and appraise the findings of various studies on Trikatu. Content COVID-19 or SARS-CoV-2 disease a pandemic principally contaminating the respiratory tract and bringing about Severe Acute Respiratory Syndrome is liable for significant mortality around the world. Far-fetched, there is no exact treatment accessible till today. Consequently, it is critical to discover the alternative methodology which can decrease the weight of illness. Trikatu powder recommended by authorities for the management of mild cases of COVID-19 is a conventional ayurvedic formulation containing three spices; Zingiber officinale, Piper nigrum, and Piper longum. A comprehensive search of the articles published since inception to 01/08/2020 on Trikatu was carried out. Major electronic medical databases such as Pub Med/MEDLINE and Cochrane Database of Systematic Reviews were used for the literature search. Summary A total of 21 records were identified by electronic searches between since inception to 01/08/2020 of which 13 records were included for review. The reviewed articles highlight Trikatu as a safe, anti-inflammatory, and immune-modulatory property by suppression of the production of pro-inflammatory cytokines TNF-a, IL-1b, IL-6, IL-17, alteration in levels of circulating immune complexes, anti-dyslipidaemia agent by reduced triglycerides and LDL cholesterol and increased HDL cholesterol, enhancing bio-availability of co-drug by reducing the elimination half-life (t1/2β) and zero time intercept of the elimination phase. Outlook The findings of this review seem to show Trikatu as a potential anti-inflammatory, anti-dyslipidaemia, and immune-modulatory ayurvedic formulation can be used for combating flu like illnesses and also in the management of COVID-19 as an adjuvant. However, rigorous double blind randomized controlled trials with larger sample size are warranted for better validation in such clinical conditions.

show abstract